Novo Nordisk AS
NOV
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
77,406
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,826.70 | 48.80 | 0.56% |
CAC 40 | 7,902.25 | 23.79 | 0.30% |
DAX 40 | 24,456.81 | 92.75 | -0.38% |
Dow JONES (US) | 44,705.19 | 246.89 | 0.56% |
FTSE 100 | 8,975.66 | 108.64 | 1.23% |
HKSE | 24,028.37 | 136.05 | 0.57% |
NASDAQ | 20,646.36 | 35.03 | 0.17% |
Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
S&P 500 | 6,285.19 | 21.93 | 0.35% |
S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
SSE Composite Index | 3,509.68 | 16.63 | 0.48% |